Medtronic PLC $MDT Shares Purchased by SS&H Financial Advisors Inc.

SS&H Financial Advisors Inc. increased its position in shares of Medtronic PLC (NYSE:MDT) by 200.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,371 shares of the medical technology company’s stock after purchasing an additional 10,915 shares during the quarter. SS&H Financial Advisors Inc.’s holdings in Medtronic were worth $1,559,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in shares of Medtronic in the first quarter valued at about $26,000. Delos Wealth Advisors LLC purchased a new stake in Medtronic during the 2nd quarter valued at about $27,000. Twin Tree Management LP purchased a new stake in Medtronic during the 1st quarter valued at about $29,000. Activest Wealth Management raised its holdings in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the last quarter. Finally, GFG Capital LLC purchased a new position in Medtronic in the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $96.52 on Monday. The firm has a market cap of $123.74 billion, a price-to-earnings ratio of 26.02, a PEG ratio of 2.54 and a beta of 0.71. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $106.33. The stock’s 50-day moving average is $97.54 and its two-hundred day moving average is $93.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the prior year, the company earned $1.26 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of Medtronic in a research report on Monday, December 15th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Friday, November 14th. Morgan Stanley boosted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Barclays increased their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, November 20th. Finally, Truist Financial dropped their target price on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.94.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).